Skip to main content

Govt building

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure access Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Wiseman, Edward, Feb. 13, 1987

 File — Box: 1, Folder: 29

Scope and Contents

Institution: Pfizer. Topics: importance of information sharing in science, even in industry; human dimension of drug creation, bringing non-steroidal anti-inflammation research to Pfizer with Joe Lombardino in 1962; major arthritis treatment regimens and drugs during 1960s, human element of understanding the systemic disease as new piece of corporate strategy to strategically develop other drugs and therapies, commercial viability of that approach;... discovering oxicams, Feldene and its pharmacokinetics; FDA approval process; human clinical trials process, setbacks; story of first Feldene patient; Lilly's failure with Oraflex; risk factors associated with drug development, technical and psychological impact of failure for a company; marketing of Feldene helped open up basic science knowledge of disease; Feldene's commercial competitors; dosing regimen and effectiveness; Feldene's sales success; Sidney Wolfe campaign against Feldene, public's fears; decline of steroidals in 1960s due to toxicity; other therapeutic uses for prednisone

See more

Dates

  • Creation: Feb. 13, 1987

Scope and Contents

Institution: Pfizer. Topics: importance of information sharing in science, even in industry; human dimension of drug creation, bringing non-steroidal anti-inflammation research to Pfizer with Joe Lombardino in 1962; major arthritis treatment regimens and drugs during 1960s, human element of understanding the systemic disease as new piece of corporate strategy to strategically develop other drugs and therapies, commercial viability of that approach;... discovering oxicams, Feldene and its pharmacokinetics; FDA approval process; human clinical trials process, setbacks; story of first Feldene patient; Lilly's failure with Oraflex; risk factors associated with drug development, technical and psychological impact of failure for a company; marketing of Feldene helped open up basic science knowledge of disease; Feldene's commercial competitors; dosing regimen and effectiveness; Feldene's sales success; Sidney Wolfe campaign against Feldene, public's fears; decline of steroidals in 1960s due to toxicity; other therapeutic uses for prednisone

See more
Expand All